(22) retrospectively analyzed a small sample set and found that the short-term efficacy in ESCC patients was not significantly correlated with the level of VEGF before treatment, and the ESCC patients whose serum VEGF decreased after treatment showed good short-term efficacy. The gene discussed is VEGFA; the disease is esophageal squamous cell carcinoma.